Phase I trial of concurrent sunitinib and radiation therapy as preoperative treatment for soft tissue sarcoma

BMJ Open

Volumn 3, Issue 9, 2013, Pages

  Jakob, Jens ^a   Rauch, Geraldine ^a   Wenz, Frederik ^b   Hohenberger, Peter ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SUNITINIB;

ANOREXIA; ARTHRALGIA; ARTICLE; BACKACHE; BLEEDING; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COUGHING; DISEASE FREE SURVIVAL; DRUG DOSE INCREASE; DYSPNEA; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEVER; HEADACHE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; INTENSITY MODULATED RADIATION THERAPY; LEUKOPENIA; LIVER FAILURE; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PANCREATITIS; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PREOPERATIVE RADIOTHERAPY; PREOPERATIVE TREATMENT; RADIATION DOSE; RECOMMENDED DRUG DOSE; SIDE EFFECT; SKIN TOXICITY; SOFT TISSUE SARCOMA; TASTE AVERSION; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 84885360593     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-003626     Document Type: Article

References (33)

1. Clark MA, Fisher C, Judson I, et al. Soft-tissue sarcomas in adults. N Engl J Med 2005;353:701-11. (Pubitemid 41175678)
2. Stiller CA, Trama A, Serraino D, et al. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer 2012;49:684-95.
3. Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol 2002;20:791-6. (Pubitemid 34111387)
4. Anaya DA, Lahat G, Wang X, et al. Postoperative nomogram for survival of patients with retroperitoneal sarcoma treated with curative intent. Ann Oncol 2010;21:397-402.
5. Mariani L, Miceli R, Kattan MW, et al. Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. Cancer 2005;103:402-8. (Pubitemid 40129301)
6. Biau DJ, Ferguson PC, Chung P, et al. Local recurrence of localized soft tissue sarcoma: a new look at old predictors. Cancer 2012;118:5867-77.
7. Ferrone ML, Raut CP. Modern surgical therapy: limb salvage and the role of amputation for extremity soft-tissue sarcomas. Surg Oncol Clin N Am 2012;21:201-13.
8. Rosenberg SA, Kent H, Costa J, et al. Prospective randomized evaluation of the role of limb-sparing surgery, radiation therapy, and adjuvant chemoimmunotherapy in the treatment of adult soft-tissue sarcomas. Surgery 1978;84:62-9. (Pubitemid 8376407)
9. Demetri GD, Antonia S, Benjamin RS, et al. Soft tissue sarcoma. J Natl Compr Canc Netw 2010;8:630-74.
10. ESMO: Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii92-9.
11. Hohenberger P, Wysocki WM. Neoadjuvant treatment of locally advanced soft tissue sarcoma of the limbs: which treatment to choose? Oncologist 2008;13:175-86. (Pubitemid 351342582)
12. Gronchi A, Lo Vullo S, Fiore M, et al. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. J Clin Oncol 2009;27:24-30.
13. O'Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 2002;359:2235-41. (Pubitemid 34717977)
14. Curtis KK, Ashman JB, Beauchamp CP, et al. Neoadjuvant chemoradiation compared to neoadjuvant radiation alone and surgery alone for Stage II and III soft tissue sarcoma of the extremities. Radiat Oncol 2011;6:91.
15. Eckert F, Matuschek C, Mueller AC, et al. Definitive radiotherapy and single-agent radiosensitizing ifosfamide in patients with localized, irresectable soft tissue sarcoma: a retrospective analysis. Radiat Oncol 2010;5:55.
16. Gronchi A, Frustaci S, Mercuri M, et al. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol 2012;30:850-6.
17. Issels RD, Lindner LH, Verweij J, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol 2010;11:561-70.
18. Penel N, Van Glabbeke M, Marreaud S. Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. Ann Oncol 2011;22:1266-72.
19. Osusky KL, Hallahan DE, Fu A, et al. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 2004;7:225-33.
20. Yoon SS, Stangenberg L, Lee YJ, et al. Efficacy of sunitinib and radiotherapy in genetically engineered mouse model of soft-tissue sarcoma. Int J Radiat Oncol Biol Phys 2009;74:1207-16.
21. DuBois S, Demetri G. Markers of angiogenesis and clinical features in patients with sarcoma. Cancer 2007;109:813-19. (Pubitemid 46333523)
22. Potti A, Ganti AK, Foster H, et al. Immunohistochemical detection of HER-2/neu, c-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas. Anticancer Res 2004;24:333-7. (Pubitemid 38279728)
23. Yudoh K, Kanamori M, Ohmori K, et al. Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer 2001;84:1610-15. (Pubitemid 32612491)
24. George S, Merriam P, Maki RG, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 2009;27:3154-60.
25. Tariq Mahmood S, Agresta S, Vigil CE, et al. Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma. Int J Cancer 2011;129:1963-9.
26. Van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879-86.
27. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
28. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62. (Pubitemid 40093472)
29. Nieder C, Wiedenmann N, Andratschke N, et al. Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treat Rev 2006;32:348-64. (Pubitemid 44063875)
30. Kao J, Packer S, Vu HL, et al. Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Cancer2009;115:3571- 80.
31. Niyazi M, Maihoefer C, Krause M, et al. Radiotherapy and "new" drugs-new side effects? Radiat Oncol 2011;6:177.
32. Jakob J, Wenz F, Dinter DJ, et al. Preoperative intensity-modulated radiotherapy combined with temozolomide for locally advanced soft-tissue sarcoma. Int J Radiat Oncol Biol Phys 2009; 75:810-16.
33. Escudier B, Roigas J, Gillessen S, et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27:4068-75.